Background. The routine use of 13-valent pneumococcal conjugate vaccination (PCV13) was implemented in children in 2010 and in adults (≥65 years of age) in 2014 in the United States. Trends in rates of penicillin G (PEN) antimicrobial nonsusceptibility (NS) for PCV13-type S. pneumoniae from adult pneumonia patients were assessed by age group.
Background. Kenya introduced 10-valent pneumococcal conjugate vaccine (PCV10) in 2011 (three doses at ages 6, 10, and 14 weeks). Impact of PCV10 on pneumococcal carriage was unknown in this setting. We assessed changes in pneumococcal carriage and antibiotic susceptibility in children aged <5 years (U5) and HIV-infected adults (HIV+ adults) post-PCV10 introduction.
Methods. During 2009-2013, we performed annual cross-sectional pneumococcal carriage surveys in two sites with ongoing population-based surveillance: Kibera (U5 only) and Lwak (U5 and HIV+ adults, catch-up vaccination for children 1-4 years offered in 2011). Nasopharyngeal swabs (and oropharyngeal swabs in adults) were obtained for culture. Pneumococcal isolates were serotyped by multiplex PCR and Quellung. Antibiotic susceptibility was determined (2009 and 2013 Results. Overall, 2,962 U5 (2,073 in Kibera, 889 in Lwak) and 2,028 HIV+ adults were enrolled. VT carriage declined by 52-60% in children 1-4 years, by 60% in children <1 year in Kibera, and by 76% in HIV+ adults (table) . PNSP carriage declined from 32.8% to 22.3% (P < 0.01) in HIV+ adults but did not change in U5 (Kibera: 77.0% vs. 75.5%, P =0.10; Lwak: 74.3% vs. 74.6%, P = 0.94).
Conclusion. The infant PCV10 program was associated with declines in VT carriage among U5 and HIV+ adults, and declines in PNSP carriage among HIV+ adults; however, VT carriage remained >10% among U5 2 years post-PCV10 introduction. Methods. For INV and N-INV pneumonia, we used a bank of Sp isolates from the SENTRY Antimicrobial Surveillance Program, where 105 centers across 40 states and nine US Census regions collected isolates from sterile or nonsterile respiratory specimen types from consecutive patients with pneumonia (one per patient). The official online US Active Bacterial Core (ABC) surveillance database for Sp was used for INV pneumococcal disease (IPD); ABCs conducts active surveillance in selected counties across 10 states in United States.
Results. Of 6,508 Sp isolates obtained from adults from the SENTRY database, 15% were from invasive pneumonia (mainly blood cultures). In 2009, PCV13 serotypes accounted for 55 and 37% of INV and N-INV pneumococcal pneumonia; in 2016 , they accounted for 25 and 23%, respectively. Between 2009 and 2016 IPD cases in adults ≥18 years; PCV13 serotypes accounted for 53% in 2009 and 25% of IPD in 2016. The correlations between IPD (ABC) with INV pneumonia (SENTRY) and N-INV pneumonia (SENTRY) were: 0.937 and 0.973 (both P < 0.01), respectively ( Table 1 ). The proportion of IPD and N-INV pneumonia due to vaccine serotypes decreased consistently and monotonically until 2014 and then plateaued (Figure 1) .
Conclusion. We found a strong correlation between databases (SENTRY and ABC) and between INV and N-INV pneumococcal disease in the proportion of disease due to PCV13 types. Our findings would need to be confirmed at the individual serotype level. The observed decrease in PCV13-type disease through 2014 is compatible with herd effect from PCV13 vaccination in children. The plateau suggests remaining disease that may be addressed by direct vaccination of adults. Surveillance of IPD alone could guide some policy on PCV13-type pneumococcal pneumonia.
